Development of an Opioid Withdrawal Clinical Outcome Assessment Among Persons With Opioid Use Disorder
Development of an Opioid Withdrawal Clinical Outcome Assessment Among Persons With Opioid Use Disorder
Withdrawal management strategies are currently the most utilized and ubiquitous intervention for opioid use disorder in the US, yet existing measures of opioid withdrawal lack Food and Drug Administration (FDA) qualification. This project will develop and validate a clinical outcome assessment (COA) for opioid withdrawal,essential for standardizing withdrawal mitigation strategies and establishing best practices. In line with the FDA's drug development tool qualification guidelines, our methodological process will involve conducting focus groups with persons with lived experience of opioid withdrawal for concept elicitation, refining these concepts through cognitive interviews, and conducting construct and longitudinal validations of the new assessment in laboratory settings and across diverse treatment contexts.
Participants with opioid use disorder will complete a two sessions in a within-subject study design to compare their responses to withdrawal questions after experiencing naloxone-precipitated withdrawal and following an overnight observation of spontaneous withdrawal. All participants will complete both sessions and the order of sessions will be randomized.
The primary outcome will be cognitive interviews, which will be conducted within 8 hours of each observation period ending to query all possible symptoms associated with the withdrawal experience.
Participants will be offered referrals to aftercare prior to study discharge and transitions to treatment programs will be facilitated whenever possible.
Inclusion Criteria:
Exclusion Criteria:
kelly.dunn@som.umaryland.edu410 ext. 202-963-1952